Research Papers:
CD1d expression on chronic lymphocytic leukemia B cells affects disease progression and induces T cell skewing in CD8 positive and CD4CD8 double negative T cells
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 2381 views | HTML 2978 views | ?
Abstract
Nadja Zaborsky1,2, Franz Josef Gassner1,2, Daniela Asslaber1,2, Petra Reinthaler1,2, Ursula Denk1,2, Sabine Flenady1,2, Josefina Piñón Hofbauer1,2, Barbara Danner1,2, Stefan Rebhandl1,2, Andrea Harrer3, Roland Geisberger1,2, Richard Greil1,2, Alexander Egle1,2
1Laboratory for Immunological and Molecular Cancer Research, Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria
2Salzburg Cancer Research Institute, Salzburg, Austria
3Department of Neurology, Paracelsus Medical University, Salzburg, Austria
Correspondence to:
Nadja Zaborsky, email: [email protected]
Keywords: CLL, T cells, T cell skewing, CD1d, CD161
Received: August 25, 2015 Accepted: June 16, 2016 Published: July 01, 2016
ABSTRACT
Chronic lymphocytic leukemia develops within a complex network driven by genetic mutations and microenvironmental interactions. Among the latter a complex interplay with the immune system is established by the clone. Next to a proposed recruitment of support from T and myeloid cells, potential anti-CLL immune reactions need to be subverted.
By using TCL1 mice as a CLL model, we show that TCR-Vβ7+ NK1.1+ T cells are overrepresented in this disease model and constitute a main subset of peripheral CD3+ cells with biased TCR usage, showing that these cells account for a major part for T cell skewing in TCL1 mice. Moreover, we show that overrepresentation is dependent on CD1d expression in TCL1 mice, implicating that these cells belong to a NKT-like cell fraction which are restricted to antigen presented by the MHC-like surface marker CD1d. Accordingly, we observed a high fraction of CD161+ cells within overrepresented T cells in CLL patients and we found downregulation of CD1d on the surface of CLL cells, both in TCL1 mice and patients. Finally, we show that in TCL1 mice, CD1d deficiency resulted in shortened overall survival. Our results point to an interaction between CLL and CD161+ T cells that may represent a novel therapeutic target for immune modulation.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 10372